Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children

Pediatric Infectious Disease Journal

Volumn 27, Issue 12, 2008, Pages 1052-1056

  Vajo, Zoltan ^a,d,e   Kosa, Lajos ^a   Szilvasy, Istvan ^a   Pauliny, Zsuzsanna ^b   Bartha, Kálmán ^b   Visontay, Ildiko ^b   Kis, Agnes ^c   Tarjan, Ildiko ^d   Rozsa, Noemi ^d   Jankovics, Istvan ^b  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b NATIONAL CENTER FOR EPIDEMIOLOGY   (Hungary)

^c Orszagos Gyogyszereszeti Intezet   (Hungary)

^d SEMMELWEIS UNIVERSITY   (Hungary)

^e State Health Center   (Hungary)

Author keywords

children; H5N1; Influenza; pandemic; vaccine

Indexed keywords

INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; INACTIVATED VACCINE;

ADOLESCENT; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL TRIAL; DRUG SAFETY; DRUG SCREENING; ECCHYMOSIS; FEMALE; FEVER; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INJECTION SITE SWELLING; MALAISE; MALE; NORMAL HUMAN; OUTCOME ASSESSMENT; PANDEMIC; PRIORITY JOURNAL; SCHOOL CHILD; SEROCONVERSION; SHIVERING; SINGLE DRUG DOSE; SKIN INDURATION; VIRUS NEUTRALIZATION; HUNGARY; IMMUNOLOGY; INFLUENZA; VACCINATION;

ADOLESCENT; CHILD; FEMALE; HUMANS; HUNGARY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; VACCINATION; VACCINES, INACTIVATED;

EID: 58149381672     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181861dd7     Document Type: Article

References (29)

1. Cumulative number of con?rmed human cases of avian in?uenza A (H5N1) reported to WHO. Available at: http://www.who.int/csr/disease/ avian-in?uenza/country/cases-table-2008-06-19/en/index.html. Accessed June 26, 2008.
2. Ungchusak K, Auewarakul P, Dowell SF, et al. Probable person-to- person transmission of avian in?uenza A (H5N1). N Engl J Med. 2005;352:333-340.
3. Yang Y, Halloran ME, Sugimoto JD, Longini IM Jr. Detecting human- to-human transmission of avian in?uenza A (H5N1). Emerg Infect Dis. 2007;13:1348-1353.
4. Dennis C. Flu-vaccine makers toil to boost supply. Nature. 2006;440: 1099.
5. WHO website. Available at: http://www.who.int/vaccine-research/ diseases/in?uenza/?u-trials-tables/en/index.html.
6. Vajo Z, Kosa L, Visontay I, Jankovics M, Jankovics I. Inactivated whole virus in?uenza A (H5N1) vaccine. Emerg Infect Dis. 2007;13:807-808.
7. Takatsy G. Puri?ed precipitated virus obtained by a new simple method. Acta Med Acad Sci Hung. 1952;3:185-191.
8. License number: OGYI-T-8998/01. Budapest, Hungary: National Institute of Pharmacology; 1995.
9. European Committee for Proprietary Medicinal Products. Note for guidance on harmonization of requirements for in?uenza vaccines, March 1997 (CPMP/BWP/214/96). European Agency for the Evaluation of Medicinal Products; March 12, 1997.
10. European Committee for Proprietary Medicinal Products. Guideline on dossier structure and content for pandemic in? uenza vaccine marketing authorisation application (CPMP/VEG/4717/03). European Agency for the Evaluation of Medicinal Products; April 5, 2004.
11. Wood JM, Schild GC, Newman RW, Seagroatt V. An improved single- radialimmunodiffusion technique for the assay of in?uenza haemagglu- tinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J Biol Stand. 1977;5:237-247.
12. European Directoriate for the Quality Medicines. European Pharma- copia. Strasbourg, France: European Directoriate for the Quality Medicines; 2007:3406-3407.
13. WHO announcement. Available at: www.who.int/mediacentre/news/ statements/2007/s14/en/index.html. Accessed July 13, 2007.
14. Kendal AP, Pereira MS, Skehel JJ, eds. Concepts and Procedures for Laboratory Based In?uenza Surveillance. Atlanta, GA: Centers for Disease Control; 1982.
15. Klimov A, Cox N. Serologic Diagnosis of In?uenza Virus Infections by Hemagglutination Inhibition. In?uenza Laboratory Course. Atlanta, GA: Centers for Disease Control; 2003.
16. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian in?uenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol. 1999;37:937-943.
17. Reed LJ, Muench H. A simple method of estimating ?fty per cent endpoints, Am J Hyg. 1938;27:493-497.
18. Walls HH, Harmon MW, Slagle JJ, Stocksdale C, Kendal AP. Characterization and evaluation of monoclonal antibodies developed for typing in?uenza A and in?uenza B viruses. J Clin Microbiol. 1986;23: 240-245.
19. Giesecke J, Sellwood C, Van-Tam J. Expert Advisory Groups on Human H5N1 Vaccines. Stockholm, Sweden: European Centre for Disease Control and Prevention. August, 2007. Available at: www.ecdc.eu.int/ publications/ technicalreports.html. 20. U.S. Food and Drug Administration. Draft Guidance on Clinical Data Needed to Support the Licensure of Pandemic In?uenza Vaccines. Available at: http://www.fda.gov/cber/gdlns/pan?uvac.html.
20. Stephenson I, Nicholson KG, Wood JM, Zambon MC, Katz JM. Confronting the avian in?uenza threat: vaccine development for a potential pandemic. Lancet Infect Dis. 2004;4:499-509.
21. Stephenson I, Nicholson KG, Glück R, et al. Safety and antigenicity of whole virus and subunit in?uenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet. 2003;362:1959- 1966.
22. Smith NM, Bresee JS, Shay DK, Uyeki TM, Cox NJ, Strikas RA. Prevention and control of in?uenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55(RR-10):1-42.
23. Poehling KA, Edwards KM, Weinberg GA, et al. The underrecognized burden of in?uenza in young children. N Engl J Med. 2006;355:31-40.
24. Baker CJ, Schaffner W, Zimmerman RK. Importance of in?uenza vaccination for children. Am Fam Physician. 2007;76:343-344.
25. Neuzil KM, Dupont WD, Wright PF, Edwards KM. Ef?cacy of inactivated and coldadapted vaccines against in?uenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J. 2001;20:733-740.
26. Centers for Disease Control and Prevention. Assessment of the effec- tiveness of the 2003-04 in?uenza vaccine among children and adults- Colorado, 2003. Morb Mortal Wkly Rep. 2004;53:707-710.
27. Voordouw AC, Sturkenboom MC, Dieleman JP, et al. Annual revacci- nation against in?uenza and mortality risk in communitydwelling elderly persons. JAMA. 2004;292:2089-2095.
28. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immungenicity of an inactivated subvirion in?uenza A (H5N1) vaccine. N Engl J Med. 2006;354:1343-1351.
29. Bresson JL, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion in?uenza A/Vietnam/1194/2004 (H5N1) vac- cine: phase I randomised trial. Lancet. 2006;367:1657-1664.